Organ-on-a-chip. Engineered Microenvironments for Safety and Efficacy Testing

Table of Contents

1. Need for alternative testing methods and opportunities for organ-on-a-chip systems 2. Cell sources and methods for producing organotypic in vitro human tissue models 3. Organs-on-a-chip engineering

Part I Organ-on-a-chip platforms to model disease pathogenesis 4. Lung-on-a-chip platforms for modeling disease pathogenesis 5. Requirements for designing organ-on-a-chip platforms to model the pathogenesis of liver disease 6. Brain-on-a-chip systems for modeling disease pathogenesis 7. Kidney-on-a-chip 8. Heart-on-a-chip 9. Caenorhabditis elegans-on-a-chip: microfluidic platforms for high-resolution imaging and phenotyping 10. Gut-on-a-chip microphysiological systems for the recapitulation of the gut microenvironment 11. Computational pharmacokinetic modeling of organ-on-chip devices and microphysiological systems

Part II Multi-organs-on-a-chip platforms to mimic humans physiology 12. Design and engineering of multiorgan systems 13. 8.b. Human body-on-a-chip systems 14. Automation and opportunities for industry scale-up of microphysiological systems 15. How to build your multiorgan-on-a-chip system: a case study

Authors

Julia Hoeng Philip Morris International, Research and Development, Neuchatel, Switzerland. Dr. Hoeng is Director of Systems Biology at Phillip Morris International and program leader. She has a profound understanding of inhalation toxicology and computational modeling of smoking-related diseases, lung cancer, COPD, and CVD. Dr. Hoeng holds a BSc in biology, MSc in bioinformatics, PhD in protein crystallography, and an executive MBA. David Bovard Scientist microphysiological systems, Philip Morris, Neuch�tel, Switzerland. David Bovard is a scientist at Philip Morris with expertise in the field of organotypic models and microfluidic systems. Before this role, David led the development of a company-owned lung/liver-on-a-chip to assess the toxicity of aerosols accurately. Manuel C. Peitsch Philip Morris International, Research and Development, Neuchatel, Switzerland. Dr. Peitsch is Chief Scientific Officer and VP of Research and Development at Philip Morris International. He has extensive experience in tobacco harm reduction, smoking-related diseases, systems biology, toxicology, bioinformatics, chemoinformatics, high-performance computing, and knowledge management. An innovation-focused results-driven biomedical research leader, Dr. Peitsch has many years of experience managing large multi-cultural teams across several countries. He holds several patents related to proteomics, genomics, and computer science and has published over 200 book chapters, technical reports, and articles in top ranking scientific journals (cited over 22000 times). He has done pioneering work in the area of molecular modeling, cell biology, computational text analytics, and systems biology/toxicology and is a founder of several initiatives, including two start-up companies, the Swiss Institute of Bioinformatics, and the [BC]2 conference (http://www.bc2.ch). He is Chairman of the Executive Board of the Swiss Institute of Bioinformatics and an active scientific advisor to several academic and commercial entities. He has also served on the Swiss National Research Council. Dr. Peitsch is a Computerworld Honors Laureate and a recipient of several awards including the New England Business and Technology Award and the United Devices Grid Visionary Award. He holds a BSc in life sciences, MSc in physical chemistry, and PhD in biochemistry. He is also Professor of Bioinformatics at the University of Basel.